Evidence map›Paper›PMID 26029666›Full record

ArticleFrontiers in oncology2015

Predictors for long-term survival free from whole brain radiation therapy in patients treated with radiosurgery for limited brain metastases.

Daniel Gorovets, Paul Rava, Daniel K Ebner, David J Tybor, Deus Cielo, Yakub Puthawala, Timothy J Kinsella, Thomas A DiPetrillo, David E Wazer, Jaroslaw T Hepel

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Brain metastases treated with radiosurgery or hypofractionated stereotactic radiotherapy: outcomes and predictors of survival.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Daniel GorovetsDepartment of Radiation Oncology, Tufts Medical Center , Boston, MA , USA ; Department of Radiation Oncology, Rhode Island Hospital , Providence, RI , USA.
Paul RavaDepartment of Radiation Oncology, UMass Memorial Medical Center , Worcester, MA , USA.
Daniel K EbnerDepartment of Radiation Oncology, Rhode Island Hospital , Providence, RI , USA.
David J TyborDepartment of Public Health and Community Medicine, Tufts University School of Medicine , Boston, MA , USA.
Deus CieloDepartment of Neurosurgery, Rhode Island Hospital , Providence, RI , USA.
Yakub PuthawalaDepartment of Radiation Oncology, Rhode Island Hospital , Providence, RI , USA.
Timothy J KinsellaDepartment of Radiation Oncology, Rhode Island Hospital , Providence, RI , USA.
Thomas A DiPetrilloDepartment of Radiation Oncology, Tufts Medical Center , Boston, MA , USA ; Department of Radiation Oncology, Rhode Island Hospital , Providence, RI , USA.
David E WazerDepartment of Radiation Oncology, Tufts Medical Center , Boston, MA , USA ; Department of Radiation Oncology, Rhode Island Hospital , Providence, RI , USA.
Jaroslaw T HepelDepartment of Radiation Oncology, Tufts Medical Center , Boston, MA , USA ; Department of Radiation Oncology, Rhode Island Hospital , Providence, RI , USA.
Rhode Island Hospital · USTufts Medical Center · USTufts University · USUMass Memorial Health Care · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo identify predictors for prolonged survival free from salvage whole brain radiation therapy (WBRT) in patients with brain metastases treated with stereotactic radiosurgery (SRS) as their initial radiotherapy approach. MATERIALS AND

methodsPatients with brain metastases treated with SRS from 2001 to 2013 at our institution were identified. SRS without WBRT was typically offered to patients with 1-4 brain metastases, Karnofsky performance status ≥70, and life expectancy ≥3 months. Three hundred and eight patients met inclusion criteria for analysis. Medical records were reviewed for patient, disease, and treatment information. Two comparison groups were identified: those with ≥1-year WBRT-free survival (N = 104), and those who died or required salvage WBRT within 3 months of SRS (N = 56). Differences between these groups were assessed by univariate and multivariate analyses.

resultsMedian survival for all patients was 11 months. Among patients with ≥1-year WBRT-free survival, median survival was 33 months (12-107 months) with only 21% requiring salvage WBRT. Factors significantly associated with prolonged WBRT-free survival on univariate analysis (p < 0.05) included younger age, asymptomatic presentation, RTOG RPA class I, fewer brain metastases, surgical resection, breast primary, new or controlled primary, absence of extracranial metastatic disease, and oligometastatic disease burden (≤5 metastatic lesions). After controlling for covariates, asymptomatic presentation, breast primary, single brain metastasis, absence of extracranial metastases, and oligometastatic disease burden remained independent predictors for favorable WBRT-free survival.

conclusionA subset of patients with brain metastases can achieve long-term survival after upfront SRS without the need for salvage WBRT. Predictors identified in this study can help select patients that might benefit most from a treatment strategy of SRS alone.

Indexed as

brain metastasesgamma knifeprognosisradiosurgeryradiotherapysurvival analysis

Identifiers

PMID26029666
PMCPMC4426730
OpenAlexW1647627703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.